Explore life science & biotech companies in Oxford, home to one of the world's leading biotechnology and life science clusters.
Pathogen genomic surveillance tools and antimicrobial resistance research
Centre for Genomic Pathogen Surveillance is a University of Oxford research centre developing genomic epidemiology methods and tools for infectious disease surveillance. Its Pathogenwatch and Microreact platforms support pathogen genome analysis, antimicrobial resistance prediction, strain clustering and visualisation…
Therapeutics to restore egg quality and improve IVF outcomes
U-Ploid Biotechnologies is an early-stage biotechnology company developing first-in-class therapeutics to address age-related decline in egg quality. Its lead programme targets chromosomal instability in human oocytes which is a primary driver of IVF failure, miscarriage, and congenital disorders in women of advanced…
Precision cancer vaccines to prevent metastatic recurrence
Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in…
Immunometabolism-targeting small molecules for autoimmune disease
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions. The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in…
Bacterial-like particle vaccine platform targeting recurrent UTIs
Spectre Bio is a biotechnology company developing a non-antibiotic prophylactic vaccine for recurrent UTIs, a major unmet medical need and significant driver of antimicrobial resistance. The company's platform produces programmable, non-replicative bacterial cells that retain a full native antigen profile while being…
Mass photometry instruments for single-molecule biomolecular characterisation
Refeyn is an analytical instrumentation company and the pioneer of mass photometry, a light-scattering technique that measures the mass of individual molecules in solution without labels. Its benchtop instruments serve pharmaceutical, biotechnology, and academic customers for characterisation of proteins, nucleic…
Magdalen College's life science and technology campus in Oxford
The Oxford Science Park is a 75-acre science and technology campus on the southern edge of Oxford, owned by Magdalen College and closely linked to the University of Oxford. Home to around 100 companies employing over 3,000 people, the park is predominantly life science focused, hosting biotechnology, medical…
Baculovirus expression systems, research reagents and contract protein production
Oxford Expression Technologies is an Oxford Brookes University and NERC spin-out specialising in recombinant protein expression. Its flashBAC baculovirus expression systems, transfer vectors and engineered insect cell lines support protein production for pharmaceutical, vaccine and diagnostic research. The company…
Generative AI and quantum chemistry platform for de novo enzyme design
Xyme is a biotechnology company developing a generative AI and quantum chemistry platform for designing novel enzymes from first principles. Its approach combines computational prediction with experimental validation to create enzymes that catalyse chemical reactions not found in nature. Applications span therapeutic…
Bacteriophage-integrated antibacterial textiles for surgical implant infection prevention
Oxford Silk Phage Technologies is a biotechnology company developing antibacterial biomaterials that integrate bacteriophages into silk-based medical textiles, for use in surgical implants and wound care devices. The technology embeds high-density cocktails of bacteriophages throughout the textile structure, producing…
Oligonucleotide therapeutics designed to upregulate protein expression
Orfonyx Bio is a biotechnology company developing genetic medicines that increase, rather than silence, the expression of therapeutic target proteins. Its platform generates antisense oligonucleotide modulators that act on regulatory elements within the untranslated regions of genes, inhibiting sequence motifs that…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…
Oxford University spinout producing cultivated beef and pork
Ivy Farm Technologies is a company developing cultivated meat using a non-GMO cell culture process originally developed at the University of Oxford. Its Oxford pilot plant operates a 600-litre bioreactor with capacity to produce 2.8 tonnes of cultivated meat annually, with products including beef burgers, sausages and…
AI-powered point-of-care genomic sequencing for hospitals and clinics
SiGenex Oxford is the UK research and development arm of SiGenex, developing an AI-powered, decentralised platform for point-of-care genomic and multi-omic diagnostics. The technology combines digital microfluidics with automated next-generation sequencing and AI-driven bioinformatics to deliver genomic results…
Automated single-cell isolation and cloning instruments for cell biology
Iota Sciences is a developer of automated single-cell handling instruments and cell-line engineering services. The company's platform automates single-cell isolation and cloning in nanolitre volumes, supporting monoclonal cell line development with integrated viability monitoring and documentation. GRID Technology…
Next-generation lipid nanoparticle platform for RNA vaccines and medicines
NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of…
GPR35 inhibitors for gastrointestinal cancer and inflammatory bowel disease
ThirtyFiveBio is a drug discovery company developing first-in-class small molecule inhibitors of GPR35, a genetically validated G protein-coupled receptor implicated in gastrointestinal disease. The company's approach targets GPR35 antagonism to prevent epithelial cell damage and dysfunction in the gut wall,…
Oxford University's biomedical start-up incubator and lab space
The BioEscalator is the University of Oxford's biomedical incubator, providing flexible laboratory and office space to early-stage life science companies on the Old Road Campus. Located between the university's medical research buildings and the Churchill and John Radcliffe hospitals, it offers shared core lab…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The technology enables large-scale, cost-effective generation of patient-derived iPSC lines from blood or skin samples, supporting disease modelling,…
AI-driven T-cell receptor discovery platform for solid tumour immunotherapies
Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell…